Agile Therapeutics, Inc. (NASDAQ:AGRX) Short Interest Up 126.7% in May

Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) saw a large growth in short interest in May. As of May 31st, there was short interest totalling 502,600 shares, a growth of 126.7% from the May 15th total of 221,700 shares. Based on an average trading volume of 403,700 shares, the short-interest ratio is currently 1.2 days. Approximately 11.4% of the company’s stock are sold short.

Several research firms have commented on AGRX. StockNews.com began coverage on shares of Agile Therapeutics in a report on Thursday, May 5th. They set a “sell” rating for the company. Maxim Group cut shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, April 8th.

Large investors have recently modified their holdings of the company. GSA Capital Partners LLP lifted its position in shares of Agile Therapeutics by 57.4% during the 3rd quarter. GSA Capital Partners LLP now owns 586,491 shares of the specialty pharmaceutical company’s stock worth $564,000 after buying an additional 213,948 shares during the last quarter. D. E. Shaw & Co. Inc. raised its position in Agile Therapeutics by 571.4% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,161,006 shares of the specialty pharmaceutical company’s stock valued at $1,055,000 after purchasing an additional 1,839,143 shares during the last quarter. Morgan Stanley raised its position in Agile Therapeutics by 3,348.3% in the 2nd quarter. Morgan Stanley now owns 769,445 shares of the specialty pharmaceutical company’s stock valued at $1,023,000 after purchasing an additional 747,131 shares during the last quarter. BlackRock Inc. raised its position in Agile Therapeutics by 2.5% in the 4th quarter. BlackRock Inc. now owns 1,507,654 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 37,394 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Agile Therapeutics by 281.3% in the 1st quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 458,300 shares during the last quarter. Institutional investors and hedge funds own 27.96% of the company’s stock.

Shares of NASDAQ:AGRX opened at $1.25 on Friday. The company has a market capitalization of $5.68 million, a PE ratio of -0.05 and a beta of 1.60. Agile Therapeutics has a twelve month low of $1.22 and a twelve month high of $63.60. The firm has a 50 day simple moving average of $5.71 and a 200-day simple moving average of $12.22.

Agile Therapeutics (NASDAQ:AGRX – Get Rating) last issued its quarterly earnings data on Wednesday, March 30th. The specialty pharmaceutical company reported ($8.00) earnings per share for the quarter, missing the consensus estimate of ($6.80) by ($1.20). The company had revenue of $1.51 million for the quarter, compared to analysts’ expectations of $1.58 million. Agile Therapeutics had a negative return on equity of 599.24% and a negative net margin of 1,209.95%. During the same quarter in the prior year, the firm posted ($8.00) EPS. As a group, equities research analysts expect that Agile Therapeutics will post -14.8 EPS for the current fiscal year.

Agile Therapeutics Company Profile (Get Rating)

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

See Also